Search

Dr. Sadelain received the award for his research on chimeric antigen receptors (CARs) and their use in providing tailored cancer treatment to patients.

… Tuesday, December 17, 2019   Michel Sadelain , Director of the Center for Cell Engineering and the incumbent of the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering, received the 2019 International Prize from Inserm (Institut national de la santé et de la recherche médicale), or the French

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

… Wednesday, April 4, 2012 A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or

Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.

… Wednesday, April 10, 2019 Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national

Learn about MSK’s leadership in developing vaccines that teach the immune system to fight cancer.

… Friday, June 6, 2025 Remarkably, the idea that a patient’s own immune system could fight cancer is more than a century old. The first notion of a cancer vaccine came back in 1893. Memorial Sloan Kettering Cancer Center (MSK) bone surgeon and cancer researcher William Coley, MD, noticed that patients

James P. Allison, Chair of the Immunology Program in the Sloan Kettering Institute, has been elected a member of the Institute of Medicine.

… Tuesday, January 1, 2008 Summary James P. Allison, Chair of the Immunology Program in the Sloan Kettering Institute, has been elected a member of the Institute of Medicine. James P. Allison, Chair of the Immunology Program in the Sloan Kettering Institute , has been elected a member of the Institute

Increased progression-free survival and a better quality of life were seen in HER2-negative metastatic breast cancer patients with a BRCA mutation who were treated with olaparib versus a single-agent chemotherapy.

… Sunday, June 4, 2017 The first phase III trial of a PARP inhibitor used to treat breast cancer reported promising data at the annual meeting of the American Society of Clinical Oncology (ASCO). Mark Robson, MD , Clinic Director of the Clinical Genetics Service and medical oncologist at Memorial Sloan

Meet MSK Clinical Nurse Margaret Bediones of MSK's Ralph Lauren Center in Harlem: “I love talking to people to educate them about the importance of cancer prevention and screening.”

… Friday, June 6, 2025 For MSK nurse Margaret Bediones, RN , taking care of people extends far beyond the walls of the MSK Ralph Lauren Center (RLC) in Harlem . She is committed to improving the health of people from underserved areas across New York City.   Born in the Philippines, Margaret’s journey

In her role at MSK, Mack will direct the evolution and improvement of all business processes.

… Monday, March 27, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that LaKisha Mack, MSHA , has joined the institution as the inaugural Chief Administrative Officer (CAO). A seasoned healthcare business leader with more than two decades of experience in institutional finance, operations

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.

… Wednesday, June 2, 2021 New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD , and colleagues found that patients who received nivolumab (Opdivo®)  after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research

The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program will facilitate tailored mentorship with MSK faculty, while providing access to MSK’s drug development expertise, resources, and a pathway for future collaboration in the MSK Therapeutics Accelerator.

… Friday, February 6, 2026 The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program